• A
• A
• A

Hormone Replacement Therapy in Postmenopausal Women May Increase the Risk of Dying from Lung Cancer (10/23/2009)
Postmenopausal women who received combined hormone replacement therapy with estrogen and progesterone were at an increased risk of dying from non–small cell lung cancer, according to the results of a study published in The Lancet.

Large-scale Screening for EGFR Mutations Can Improve Outcomes in Lung Cancer (08/31/2009)
Large-scale screening for epidermal growth factor receptor mutations in lung cancer is feasible and allows for customization of treatment with Tarceva® (erlotinib), thereby improving outcomes, according to the results of a study published in the New England Journal of Medicine.

Iressa® Superior to Paraplatin®/Taxol® in Advanced NSCLC (08/27/2009)
First-line treatment with Iressa® (gefitinib) improves progression-free survival over combination treatment with Paraplatin® (carboplatin) and Taxol® (paclitaxel) in advanced non–small cell lung cancer (NSCLC) among nonsmokers and former light smokers in East Asia, according to the results of a study published in the New England Journal of Medicine.

Schizophrenia Associated with Increased Cancer Mortality (07/24/2009)
Patients with schizophrenia appear to have an increased risk of mortality from cancer, especially breast cancer in women and lung cancer in men, according to the results of a study published in Cancer.

False-positive Results Are Common with Cancer Screening (07/20/2009)
The risk of obtaining a false-positive result from screening for prostate, lung, colorectal, and ovarian cancer is high and becomes cumulatively higher with ongoing screening—after 14 screening tests, the cumulative risk of a false-positive is 60.4% for men and 48.8% for women, according to the results of a study published in the Annals of Family Medicine.

▪ More...

Addition of Avastin® to Tarceva® Does Not Appear to Improve Survival in Patients with Advanced Non–Small Cell Lung Cancer (10/06/2008)
According to the results of a Phase III clinical trial, treatment with Avastin® (bevacizumab) plus Tarceva® (erlotinib) did not result in better survival than treatment with Tarceva alone among patients with advanced non–small cell lung cancer (NSCLC) whose disease had progressed following platinum-based chemotherapy. These results were recently published in a press release by Genentech.

Bone Marker Associated with Survival in Breast, Prostate, and Lung Cancers (06/23/2008)
The bone marker N-telopeptide of type I collagen (NTX) is associated with skeletal-related events and survival among patients with cancer that has spread to the bone (bone metastases).  Improved outcomes may be achieved by reducing these markers through treatment with agents such as Zometa® (zoledronic acid). These results were recently published in the journal Cancer.

Nexavar® Improves Survival in Recurrent Non–Small Cell Lung Cancer (06/06/2008)
Patients with recurrent non–small cell lung cancer (NSCLC) who were treated with Nexavar® (sorafenib) experienced a delay in disease progression and a possible improvement in overall survival. These findings were reported at the 2008 annual meeting of the American Society of Clinical Oncology.

Addition of Avastin® Superior to Chemotherapy Alone in Lung Cancer (10/15/2007)
According to an article recently published in the Journal of Clinical Oncology, the addition of Avastin® (bevacizumab) to Tarceva® (erlotinib) or to chemotherapy improves survival compared with chemotherapy alone in the treatment of recurrent non–small cell lung cancer.

Iressa® and Taxotere® Provide Same Survival in Recurrent Non–Small Cell Lung Cancer (09/06/2007)
According to results presented at the 2007 annual International Association for the Study of Lung Cancer (IASLC), Iressa® (gefitinib) may provide equal outcomes with an improved quality of life compared to Taxotere® (docetaxel) for the treatment of recurrent non–small cell lung cancer among patients who have received one prior treatment regimen.

▪ More...

Hormone Replacement Therapy in Postmenopausal Women May Increase the Risk of Dying from Lung Cancer (10/23/2009)
Postmenopausal women who received combined hormone replacement therapy with estrogen and progesterone were at an increased risk of dying from non–small cell lung cancer, according to the results of a study published in The Lancet.

Schizophrenia Associated with Increased Cancer Mortality (07/24/2009)
Patients with schizophrenia appear to have an increased risk of mortality from cancer, especially breast cancer in women and lung cancer in men, according to the results of a study published in Cancer.

False-positive Results Are Common with Cancer Screening (07/20/2009)
The risk of obtaining a false-positive result from screening for prostate, lung, colorectal, and ovarian cancer is high and becomes cumulatively higher with ongoing screening—after 14 screening tests, the cumulative risk of a false-positive is 60.4% for men and 48.8% for women, according to the results of a study published in the Annals of Family Medicine.

Lung Cancer Screening with Low-dose Computed Tomography Associated with High Rate of False Positives (06/10/2009)
Individuals who undergo lung cancer screening with low-dose computed tomography (LDCT) are at a high risk for receiving false-positive results, according to the results of a study presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida.

Removal of Ovaries During Hysterectomy for Benign Condition Carries Health Risks (05/12/2009)
Among women who have a hysterectomy for reasons other than cancer, those who also have their ovaries removed have a slightly higher overall risk of death from cancer and heart disease than those who do not have their ovaries removed. These results were published in Obstetrics and Gynecology.

▪ More...

Iressa® Superior to Paraplatin®/Taxol® in Advanced NSCLC (08/27/2009)
First-line treatment with Iressa® (gefitinib) improves progression-free survival over combination treatment with Paraplatin® (carboplatin) and Taxol® (paclitaxel) in advanced non–small cell lung cancer (NSCLC) among nonsmokers and former light smokers in East Asia, according to the results of a study published in the New England Journal of Medicine.

Tarceva® Maintenance Therapy Improves Overall Lung Cancer Survival (07/14/2009)
In a Phase III clinical trial, patients with advanced non–small cell lung cancer lived longer if they received treatment with Tarceva® (erlotinib) immediately following initial chemotherapy. These results were made available in a press release from Roche.

Alimta® Approved as Lung Cancer Maintenance Therapy (07/07/2009)
The U.S. Food and Drug administration (FDA) has expanded the approval of the chemotherapy drug Alimta® (pemetrexed) to include maintenance therapy for locally advanced or metastatic, nonsquamous, non-small cell lung cancer.

Zactima™ Shows Promise Against Non–Small Cell Lung Cancer (06/04/2009)
According to the results of a Phase III clinical trial presented at the 2009 annual meeting of the American Society of Clinical Oncology (ASCO), addition of the investigational targeted therapy Zactima™ (vandetanib) to chemotherapy with Taxotere® (docetaxel) delayed cancer progression among patients with previously treated, advanced non–small cell lung cancer.

Study Assesses Risk of Gastrointestinal Perforation in Patients Treated with Avastin® (05/28/2009)
Gastrointestinal perforation is a potentially serious side effect of the targeted therapy Avastin® (bevacizumab). To explore how frequently this side effect occurs, a study published in Lancet Oncology evaluated information from 17 clinical trials. The results indicate that Avastin users are roughly twice as likely as nonusers to experience gastrointestinal perforation but that the risk appears to vary by Avastin dose and tumor type.

▪ More...

Large-scale Screening for EGFR Mutations Can Improve Outcomes in Lung Cancer (08/31/2009)
Large-scale screening for epidermal growth factor receptor mutations in lung cancer is feasible and allows for customization of treatment with Tarceva® (erlotinib), thereby improving outcomes, according to the results of a study published in the New England Journal of Medicine.

PET/CT Improves Detection of Inoperable Lung Cancer (07/02/2009)
Preoperative lung cancer staging with combined PET/CT imaging allows some patients to avoid futile surgery. These results were published in the New England Journal of Medicine.

Combined Hormone Replacement Therapy Linked to Increased Death Rate from NSCLC (06/04/2009)
Menopausal women with non–small cell lung cancer (NSCLC) who receive combined hormone replacement therapy with estrogen plus progestin are 61% more likely to die from the disease than their counterparts who received placebo, according to the results of a study presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida.

Adjuvant Paclitaxel plus Carboplatin Does Not Improve Survival in Stage IB NSCLC (01/15/2009)
Adjuvant chemotherapy does not provide a statistically significant survival advantage for patients with Stage IB non–small cell lung cancer (NSCLC), according to the results of a study published in the Journal of Clinical Oncology.

Stereotactic Radiation Improves Local Control but Not Survival in Lung Cancer (09/25/2008)
The addition of stereotactic radiation therapy in early-stage non–small cell lung cancer (NSCLC) improves disease control at the site of cancer and appears to reduce NSCLC-related deaths but does not improve overall survival. These results were recently presented at the 2008 annual American Society of Therapeutic Radiology and Oncology (ASTRO).

▪ More...